Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All)

Bortolozzi, Roberta; Mattiuzzo, Elena; Trentin, Luca; Accordi, Benedetta; Basso, Giuseppe; Viola, Giampietro

doi:10.1016/j.bcp.2018.01.050

Cited by 28 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 It will also be interesting to see if the addition of immunotherapy to frontline treatments will be able to improve the survival rates of ALL and to reduce relapse rates, even in good MRD responders in which relapse is rather unexpected. 9,10 Unfortunately, the low number of patients in this series did not allow us to address this issue (only 13 patients received allo-HSCT).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, these patients might benefit from targeted therapies with CDK4/6 inhibitors in combination with chemotherapeutic agents, which have demonstrated cell cycle arrest and induction of apoptosis in primary BCP-ALL cell cultures. 11 It will also be interesting to see if the addition of immunotherapy to frontline treatments will be able to improve the survival rates of ALL and to reduce relapse rates, even in good MRD responders in which relapse is rather unexpected.…”

Section: Discussionmentioning

confidence: 99%

“…These results are similar to those reported by the GRAALL group, which identified IKZF1 partial gene deletions as markers of relapse propensity independent of MRD. 12 GIMEMA group, 11 showing that CNA analyses provided prognostic information about the ALL risk, otherwise unknown by conventional cytogenetics. Given that IKZF1, EBF1, and BTG1 deletions are enriched in Ph-like ALL, the refractoriness of patients harboring these deletions may reflect the intrinsic resistance to conventional therapy of this BCP-ALL subtype.…”

Section: Discussionmentioning

confidence: 99%

“…GIMEMA group,11 showing that CNA analyses provided prognostic information about the ALL risk, otherwise unknown by conventional cytogenetics. GIMEMA group,11 showing that CNA analyses provided prognostic information about the ALL risk, otherwise unknown by conventional cytogenetics.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia

Ribera

Zamora

Vives

et al. 2019

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Minimal residual disease (MRD) assessment is an essential tool in contemporary acute lymphoblastic leukemia (ALL) protocols, being used for therapeutic decisions such as hematopoietic stem cell transplantation in high‐risk patients. However, a significant proportion of adult ALL patients with negative MRD still relapse suggesting that other factors (ie, molecular alterations) must be considered in order to identify those patients with high risk of disease progression. We have identified partial IKZF1 gene deletions and CDKN2A/B deletions as markers of disease recurrence and poor survival in a series of uniformly treated adolescent and adult Philadelphia chromosome‐negative B‐cell progenitor ALL patients treated according to the Programa Español de Tratamientos en Hematología protocols. Importantly, CDKN2A/B deletions showed independent significance of MRD at the end of induction, which points out the need for treatment intensification in these patients despite being MRD‐negative after induction therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia

Ribera

Zamora

Vives

et al. 2019

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

show abstract

“…Ribociclib, another CDK4/CDK6 kinase inhibitor, enhanced glucocorticoid sensitivity in primary cultures derived from bone marrow of pediatric B-precursor ALL patients (96). A recent study showed that palbociclib suppressed dissemination of Ph+ ALL and prolonged survival in a xenograft model (97).…”

Section: Other Targeted Approachesmentioning

confidence: 99%

Molecular Approaches to Treating Pediatric Leukemias

2019

View full text Add to dashboard Cite

Over the past decades, striking progress has been made in the treatment of pediatric leukemia, approaching 90% overall survival in children with acute lymphoblastic leukemia (ALL) and 75% in children with acute myeloid leukemia (AML). This has mainly been achieved through multiagent chemotherapy including CNS prophylaxis and risk-adapted therapy within collaborative clinical trials. However, prognosis in children with refractory or relapsed leukemia remains poor and has not significantly improved despite great efforts. Hence, more effective and less toxic therapies are urgently needed. Our understanding of disease biology, molecular drivers, drug resistance and, thus, the possibility to identify children at high-risk for treatment failure has significantly improved in recent years. Moreover, several new drugs targeting key molecular pathways involved in leukemia development, cell growth, and proliferation have been developed and approved. These striking achievements are linked to the great hope to further improve survival in children with refractory and relapsed leukemia. This review gives an overview on current molecularly targeted therapies in children with leukemia, including kinase, and proteasome inhibitors, epigenetic and enzyme targeting, as well as apoptosis regulators among others.

show abstract

Monoclonal Antibody-Based Treatment and Other New Agents for B-Lineage Acute Lymphoblastic Leukemia

Molina

Shah

2022

Clinical Management of Acute Lymphoblastic Leukemia

View full text Add to dashboard Cite

Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All)

Cited by 28 publications

References 32 publications

Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia

Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia

Molecular Approaches to Treating Pediatric Leukemias

Monoclonal Antibody-Based Treatment and Other New Agents for B-Lineage Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About